This scorecard rates the pace of change in Australia against the seven recommendations of the 2021 CGT: Rising to the challenge white paper, with 16 expert informed and endorsed indicators. These indicators are designed to be measured against progress in the coming years.

Cell and Gene Therapies, or CGTs, are at the forefront of medical innovation. Unlike conventional medicines, these powerful new therapies target a patient’s own immune cells or genes to deliver long-lasting therapeutic, or at times, curative benefits, treating a range of health conditions such as some cancers, genetic disorders, chronic diseases and more.

The research reveals that Australia’s health system will struggle to deliver on the promise of these innovative therapies without significant change. If we want to harness their potential to improve the health of Australians, an urgent focus on system change is necessary.